Polyrizon Announces Strategic Plan to Pursue Revenue‑Generating Investments While Advancing Core Medical Pipeline

Polyrizon Ltd. (Nasdaq: PLRZ), a pre‑clinical‑stage biotechnology company focused on developing intranasal protective solutions, announced on January 13, 2026 that its Board of Directors has authorized the exploration of strategic investment opportunities in select revenue‑generating businesses. The company plans to initially target high‑growth sectors such as defense, aviation, and artificial intelligence (AI) as part of its broader capital allocation strategy. Despite this new direction, Polyrizon emphasized that it remains fully committed to advancing its core medical device pipeline, including continuing product development, preclinical and clinical studies, and regulatory progress for key programs such as PL‑14 (allergy blocker), PL‑16 (viral blocker), and the Trap & Target intranasal drug delivery platform. The board said it will leverage the company’s strong cash position and debt‑free balance sheet to pursue selective investments expected to generate near‑term revenue, enhance financial stability, and create additional value for shareholders — all while maintaining focus on its primary medical mission. Polyrizon’s proprietary Capture and Contain (C&C) hydrogel technology underpins its nasal spray products, forming a barrier to help block viruses and allergens. The company also continues development of its Trap & Target™ technology for intranasal delivery of therapeutic compounds. #Polyrizon #BiotechInvestments #RevenueGrowth #MedicalInnovation #SlimScan #GrowthStocks #CANSLIM